Jonathan Rubin
Chief Tech/Sci/R&D Officer chez SUPERNUS PHARMACEUTICALS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Jonathan Rubin's current job is Senior VP-R&D, Chief Medical Officer at Supernus Pharmaceuticals, Inc. He previously worked as a Medical Director at Shire Development LLC, Chief Medical Officer at Alcobra Ltd., and Chief Medical Officer at Atentiv, Inc. Dr. Rubin received his undergraduate degree from Yale University, his MBA from Columbia Business School, and his doctorate from The University of Connecticut School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASHTROM GROUP LTD.
0,14% | 29/06/2023 | 144 849 ( 0,14% ) | 2 M $ | 31/03/2024 |
| 23/02/2024 | 4 641 ( 0,01% ) | 158 305 $ | 31/03/2024 |
Postes actifs de Jonathan Rubin
| Sociétés | Poste | Début |
|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Anciens postes connus de Jonathan Rubin
| Sociétés | Poste | Fin |
|---|---|---|
| Atentiv, Inc. | Chief Tech/Sci/R&D Officer | 01/02/2020 |
Alcobra Ltd.
 Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Chief Tech/Sci/R&D Officer | 01/09/2017 |
| Shire Development LLC | Chief Tech/Sci/R&D Officer | - |
Formation de Jonathan Rubin
| Yale University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
| The University of Connecticut School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SUPERNUS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Health Technology |
| Atentiv, Inc. | |
| Shire Development LLC |
